Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• KER-065 granted FDA Orphan Drug designation for DMD

  KER-065, an experimental Duchenne muscular dystrophy (DMD) drug, has been granted Orphan Drug designation by the FDA.

• Dyne Therapeutics receives Breakthrough Therapy designation for DYNE-251

  DYNE-251, developed by Dyne Therapeutics and aimed at treating DMD, has received a Breakthrough Therapy Designation.

• Case report examines acute respiratory distress in a teenage girl with DMD

  A recent case report examines the rare case of a teenage girl with DMD that was complicated by acute respiratory distress syndrome.

• Sarepta voluntarily pauses Elevidys shipments in the US

  Sarepta Therapeutics has announced that it will voluntarily stop all shipments of the DMD therapeutic agent Elevidys.

• New study provides insights into beta-blocker therapy efficacy in DMD

  Beta-blocker therapy appears to be beneficial in the context of Duchenne muscular dystrophy (DMD) complicated by cardiac dysfunction.

• DMD associated with high household costs that rise as the disease advances

  Accommodating the functional impairments associated with DMD appears to involve substantial costs for households.

• Higher cholesterol levels associated with decreased bone density in DMD

  Cholesterol and triglyceride levels appear to be inversely correlated with bone density in patients with Duchenne muscular dystrophy (DMD).

• Parents and patients have mixed opinions on preventative bisphosphonates for DMD

  Boys with DMD, their parents and health professionals have a mix of perspectives on the use of bisphosphonates to prevent osteoporosis.

• Muscle contractures linked to gait abnormalities in DMD

  Muscle contractures contribute significantly to walking (gait) abnormalities in patients with Duchenne muscular dystrophy (DMD).

• Home ventilation slows respiratory deterioration in DMD

  Initiation of home mechanical ventilation around the age of 20 appears to slow respiratory deterioration in patients with DMD.